Scarica l'app Stockscreener
4.56
1.79%
0.08
Dopo l'orario di chiusura:
4.56
Precedente Chiudi:
$4.48
Aprire:
$4.48
Volume 24 ore:
103.25K
Relative Volume:
0.45
Capitalizzazione di mercato:
$163.48M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+5.31%
1M Prestazione:
+0.00%
6M Prestazione:
+0.88%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.47
$4.58
Intervallo di 1 settimana:
$4.25
$4.58
Portata 52W:
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Nome
Bioage Labs Inc
Settore
Telefono
510-806-1445
Indirizzo
5885 HOLLIS STREET, EMERYVILLE
Confronta BIOA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
4.56 | 155.59M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
152.44 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2024-12-10 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-21 | Iniziato | Citigroup | Buy |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-21 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioage Labs Inc Borsa (BIOA) Ultime notizie
What is BioAge Labs Inc. s revenue forecast3x Potential Swing Trade Ideas - newsyoung.net
BioAge Labs Reports Q2 2025 Financial Results and Progress - TipRanks
Q3 EPS Estimates for BioAge Labs Decreased by William Blair - MarketBeat
Smart tools for monitoring BioAge Labs Inc.’s price actionAI-Powered Stock Trend Movement Analysis - Newser
What makes BioAge Labs Inc. stock price move sharplyFree Growth Focused Entry Plan Suggestions - Newser
Cautious Outlook on BioAge Labs, Inc. Amid Uncertainties in Clinical Developments and Market Perception - TipRanks
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M - The Motley Fool
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M - Nasdaq
BioAge Labs, Inc. Advances Clinical Pipeline with BGE-102 Phase 1 Trial Set for 2H 2025 and Expands APJ Agonist Pipeline - Quiver Quantitative
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs Q2 2025: BGE-102 on track for Phase 1, expanded APJ pipeline, strengthened discovery platform. - AInvest
BioAge Labs Pipeline Expands: Key NLRP3 Drug Enters Clinical Phase, Secures 4-Year Cash Runway - Stock Titan
Full technical analysis of BioAge Labs Inc. stockFree Fundamental Growth Stock Analysis - Newser
What are the technical indicators suggesting about BioAge Labs Inc.Maximize your returns with expert insights - Jammu Links News
What catalysts could drive BioAge Labs Inc. stock higher in 2025Dynamic investment growth - Jammu Links News
What is BioAge Labs Inc. company’s growth strategyHigh-margin investment plays - Jammu Links News
How does BioAge Labs Inc. compare to its industry peersDiscover undervalued stocks before they soar - Jammu Links News
Is BioAge Labs Inc. a growth stock or a value stockSkyrocketing returns - Jammu Links News
Should I hold or sell BioAge Labs Inc. stock in 2025Rapid market gains - Jammu Links News
What are the latest earnings results for BioAge Labs Inc.Navigate the market with precision tools - Jammu Links News
BioAge Labs Requests to Dismiss Class Action Filed by Investors - TradingView
BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery - MSN
Published on: 2025-07-29 06:11:56 - beatles.ru
Price Channel Expanding on BioAge Labs Inc.’s ChartAccurate Buy Point for Momentum Stocks Detected - beatles.ru
BioAge to Analyze Over 17,000 Biobank Samples for Drug Discovery - AInvest
How to interpret RSI for BioAge Labs Inc. stockFree Trade Ready Stock Watch for Short Term - Newser
Published on: 2025-07-29 09:16:13 - metal.it
Can BioAge Labs Inc. Bounce Back From Weekly LowWeekly Top Gainers Forecast Watchlist Released - metal.it
Will BioAge Labs Inc. Benefit From Sector TailwindsReal Time Stock Movement Analysis Indicates Breakout - metal.it
Competitive Positioning of BioAge Labs Inc.: Is It Leading or LaggingLow Risk Entry Points - metal.it
How strong is BioAge Labs Inc. company’s balance sheetInvest confidently with data-backed picks - Jammu Links News
Bioage Labs Inc Azioni (BIOA) Dati Finanziari
Non sono disponibili dati finanziari per Bioage Labs Inc (BIOA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Bioage Labs Inc Azioni (BIOA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pande Vijay Satyanand | Director |
Oct 01 '24 |
Buy |
19.73 |
126,793 |
2,501,626 |
1,026,793 |
| Pande Vijay Satyanand | Director |
Oct 02 '24 |
Buy |
19.73 |
67,096 |
1,323,804 |
1,093,889 |
| Pande Vijay Satyanand | Director |
Oct 03 '24 |
Buy |
19.90 |
25,306 |
503,589 |
1,119,195 |
| Cormorant Asset Management, LP | Former 10% Owner |
Sep 27 '24 |
Buy |
18.00 |
450,000 |
8,100,000 |
1,629,529 |
| Pande Vijay Satyanand | Director |
Sep 27 '24 |
Buy |
18.00 |
900,000 |
16,200,000 |
900,000 |
| ENRIGHT PATRICK G | Director |
Sep 27 '24 |
Buy |
18.00 |
400,000 |
7,200,000 |
1,710,589 |
| HEALY JAMES | Director |
Sep 27 '24 |
Buy |
18.00 |
666,665 |
11,999,970 |
2,227,124 |
4.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):